February 9, 2018
Immutep’s efti combination with Keytruda is safe, DSMB says
Immutep Limited’s combination of eftilagimod alpha with pembrolizumab (KEYTRUDA) is safe and well tolerated at doses up to 30 mg…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
February 8, 2018
ViiV Healthcare sues Gilead over HIV drug containing bictegravir patent infringmenet, Gilead increases dividend 10% after posting net loss in Q4 2017
ViiV Healthcare on Thursday said it has filed patent infringement litigation against Gilead Sciences Inc. over bictegravir in the United…
February 8, 2018
Novartis to update plaque psoriasis inhibitor Cosentyx
Novartis got an approval from the USFDA for a label update for its plaque psoriasis inhibitor Cosentyx (secukinumab).
February 8, 2018
Circassia reaches new customers in USA through Vizient
Circassia Pharmaceuticals has received a multi-year Innovative Technology contract for its Niox Vero asthma management products from Vizient.
February 8, 2018
Pharmapack Europe Award Winners 2018
Pharmapack Europe announced the winners of the much celebrated 2018 Pharmapack Awards. Due to the outstanding quality of entries, six worthy…
February 7, 2018
Sobi nets deal with Republic of Ireland to provide its therapies for haemophilia
Republic of Ireland’s Health Service Executive (HSE) and Sobi have signed a supply deal to offer people with with haemophilia haemophilia…
February 7, 2018
Form of vitamin B3 shows improvements in treating Alzheimer’s – on mouse model
Alzheimer’s disease can be with prevended neurological damage and improved cognitive and physical function with the supplement nicotinamide riboside (NR)…
February 6, 2018
Idorsia six months after demerger from Actelion posts €12M net loss, announces investing in pipeline and OPEX of €336M in 2018
Idorsia Ltd has made meaningful collaboration with industry leaders in the six and a half months since the demerger from…
February 5, 2018
Shield disappointed with Feraccru study results
Shield Therapeutics reported the results from its AEGIS-CKD pivotal Phase III study of Feraccru, a novel oral ferric iron therapy…
February 5, 2018
BMS’s study for Opdivo combination with Yervoy for non-small cell lung cancer meets endpoint
Bristol-Myers Squibb said Monday that its Phase 3 CheckMate -227 study met its co-primary endpoint of progression-free survival (PFS) with…